Authors
Latest:
BGB-11417 +/- Zanubrutinib Demonstrates Early Efficacy Signals in CLL/SLLPhase 1 clinical trial data shows that BGB-11417 may induce response and lead to minimal residual disease negativity in patients with chronic lymphocytic leukemia.
Latest:
PSMA-Directed Therapies and Diagnostics Expand Their Scope in Prostate CancerWith the emergence of therapies that target PSMA, a cell surface transmembrane protein that is overexpressed in most prostate cancer cells, particularly in castration-resistant disease, the ability to detect and treat the disease has been transformed.
Latest:
Considering Radiation and Preoperative Therapy Options in Locally Advanced GEJ CancersWeijing Sun, MD, discusses a major topic in locally advanced gastroesophageal junction adenocarcinoma covered at the 2018 ISGIO Annual Conference in Arlington, Virginia.
Latest:
Current Management of Pancreatic CancerRecent therapeutic advances have almost doubled the survival of patients with metastatic pancreatic cancer, and the availability of highly active chemotherapy regimens is making personalized medicine a reality.
Latest:
FDA Issues Draft Guidance to Broaden Clinical Trial InclusionThe FDA recently released 5 new draft guidance documents that promote broader patient eligibility for cancer clinical trials. The policies encourage inclusion of certain individuals who were previously disqualified due to medical conditions or biological factors, including brain metastases, organ dysfunction, prior or concurrent malignancies, chronic infections, and age.
Latest:
Detecting the MET Exon 14 Skipping Mutations in NSCLCWillemina R. Geurts-Giele, PhD, discusses 2 approaches used to detect the MET exon 14 skipping mutation in patients with non-small cell lung cancer.
Latest:
Olaratumab Plus Doxorubicin in Advanced Soft Tissue SarcomaWilliam D. Tap, MD, discusses results from a phase Ib/II presented at the 2015 Connective Tissue Oncology Society (CTOS) Annual Meeting.
Latest:
Exploring Why Venetoclax and Ibrutinib Have Synergy in the CLL PopulationWilliam G. Wierda, MD, PhD, discusses the synergy between ibrutinib and venetoclax in patients with chronic lymphocytic leukemia.
Latest:
Choosing Therapies for Early-Stage HER2+ Breast CancerWilliam J. Gradishar, MD, discusses the choice of adjuvant or neoadjuvant regimens for patients with HER2-positive breast cancer.
Latest:
Addressing Challenges With New Therapies in Prostate CancerWilliam K. Oh, MD, discusses phase III studies in the prostate cancer setting which led to the use of these new treatments, such as androgen receptor targeted therapies with chemotherapy in earlier disease settings.
Latest:
Evaluating Significance of ENZAMET Trial in Metastatic Hormone-Sensitive Prostate CancerWilliam K. Oh, MD, discusses the rationale for presenting the data for the phase III ENZAMET trial in a plenary session at the 2019 ASCO Annual Meeting. He says these data were significant because it was a large randomized clinical trial for the treatment of newly diagnosed patients with metastatic hormone-sensitive prostate cancer.
Latest:
Selecting Therapy for Patients with CRPCWilliam Kevin Kelly, DO, professor of medical oncology and urology, Thomas Jefferson University, discusses the possibility of preselecting which castration-resistant prostate cancer (CRPC) patients will be sensitive to chemotherapy or hormone therapy.
Latest:
Incorporating Biomarker Testing in Community Cancer Clinics: A Real-World Pilot StudyAlthough there is tremendous excitement about boundaries of science stretching beyond human imagination, realizing the real-world impact of scientific advancement on the health outcomes of patients provides a reality check on how far we still must go.
Latest:
Dr. William Sikov on Triple-Negative Breast Cancer Patients Not Responding to TreatmentWilliam Sikov, MD, associate director of Clinical Research, Program in Women
Latest:
Dr. William Wierda on Ibrutinib and Idelalisib as Treatments in NSCLCWilliam G. Wierda, MD, PhD, discusses ibrutinib and idelalisib as treatments for non-small cell lung cancer. Wierda says that as it currenlty stands, ibrutinib is approved only for patients with NSCLC with a 17p deletion untreated and idelalisib is only approved for patients with untreated NSCLC.
Latest:
Treatments Improve PFS in Thyroid CancerWinston Tan, MD, discusses 2 agents that have advanced the treatment landscape for patients with thyroid cancer, including the multi-tyrosine kinase inhibitor lenvatinib and another TKI, sorafenib.
Latest:
Exploring Immunotherapy in Brain CancerW. K. Alfred Yung, MD, a professor of Neuro-oncology at MD Anderson Cancer Center, discusses the future of immuno-oncology in the treatment landscape of brain cancer.
Latest:
Use of Somatostatin Analogs in Patients With Neuroendocrine TumorsWouter W. de Herder, MD, PhD, professor of Endocrine Oncology, Erasmus MC, discusses the use of somatostatin analogs in patients with neuroendocrine tumors, as well as significant clinical trials investigating these agents.
Latest:
Current Role of MET Inhibitors in Cancer TherapyEmerging discoveries of MET chromosomal fusions provide additional promise as therapeutic genomic targets in MET cancer therapy and would need to be tested vigorously.
Latest:
Dr. Meng Discusses the Significance of MRI-US Fusion Targeted Biopsies in Prostate CancerXiaosong Meng, MD, PhD, NYU Langone Medical Center, discusses MRI-US fusion targeted biopsies in high-grade prostate cancer.
Latest:
Teclistamab With Talquetamab Shows a Manageable Safety Profile in RRMMYael Cohen, MD, discusses the main safety findings from the phase 1/2 RedirecTT-1 trial, which is evaluating the combination of teclistamab-cqyv and talquetamab for the treatment of patients with relapsed/refractory multiple myeloma.
Latest:
Dr. Yardena Samuels on Targeting Pathways Instead of Proteins in MelanomaYardena Samuels, PhD, on the ineffectiveness of targeting a single gene of proteins in patients with melanoma. Samuels says this strategy may work for the short term for treatment, but patients would tend to develop a resistance much quicker to treatment strategies using this method.
Latest:
Biomarker Testing Varies at Community/Academic Centers for Gastric CancerYelena Y. Janjigian, MD, discusses the differences between biomarker testing at academic centers versus community centers for patients with gastric cancer.
Latest:
Does COSMIC-313 Make the Case for Triplet Therapy in RCC?Yousef Zakharia, MD, discusses the COSMIC-313 study and its implications to date.
Latest:
Nab-Paclitaxel as Neoadjuvant Therapy for Breast CancerYu (Amy) Zong, Shanghai Jiaotong University School of Medicine, discusses a meta-analysis of nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer.
